جست‌وجوی استاد و پژوهشگر

• Pulmonary Hypertension
• Clinical Biomarkers
• Combination Therapy
• +۳ مورد دیگر

Terence Trow, M.D., is an Associate Clinical Professor of Medicine and Director of the Pulmonary Vascular Disease Program at Yale School of Medicine. His expertise lies in pulmonary hypertension, particularly clinical biomarkers and combination therapies. He holds academic appointments in the Department of Pulmonary, Critical Care & Sleep Medicine and contributes to the Winchester Center for Lung Disease and Lysosomal Disease & Inherited Metabolic Liver Disease Program. Dr. Trow graduated summa cum laude from Bowdoin College (Biochemistry, 1982) and earned his MD from Dartmouth Medical School (1986). He trained in Internal Medicine at New York Hospital-Cornell University Medical College and completed Pulmonary/Critical Care Fellowship at Yale. His research focuses on advancing diagnostic criteria and therapeutic strategies for pulmonary arterial hypertension. He has authored over 40 peer-reviewed articles, including seminal work on biomarkers and guideline-driven therapies. His editorial roles include Deputy Editor of Proceedings of the American Thoracic Society and contributions to Clinical Pulmonary Medicine . Dr. Trow has received multiple accolades, including Fellowships from the American College of Physicians and American College of Chest Physicians. He has been named Attending of the Year at two major hospitals and actively participates in national organizations like the Pulmonary Hypertension Association. His clinical practice emphasizes multidisciplinary care for complex pulmonary vascular diseases. He collaborates with teams at the Yale Pulmonary Hypertension Center and has pioneered programs at Yale and Stony Brook.

Michael Dahabiehمشاهده پروفایل

پژوهشگر ارشد

• Cancer Biology
• Metabolic Research
• Molecular Biology
• +۳ مورد دیگر

Dr. Michael Dahabieh is a Postdoctoral Fellow in the Russell Jones Laboratory , where he continues exploring intersections between cancer biology and metabolic research. He earned his Ph.D. in experimental medicine from McGill University and holds M.Sc. and B.Sc. degrees in molecular biology and biochemistry from Simon Fraser University . Education Ph.D., McGill University (experimental medicine) M.Sc., Simon Fraser University (molecular biology and biochemistry) B.Sc., Simon Fraser University (molecular biology and biochemistry) His research focuses on peroxisomes in tumor proliferation , CD8+ T cell metabolism , and nutrient-driven immune responses . His work employs techniques like immunoprecipitation , immunofluorescence , and flow cytometry to dissect metabolic pathways in cancer and immune cells. Recent publications highlight his contributions to understanding CD8+ T cell exhaustion , nutrient utilization , and metabolic reprogramming in tumor environments. His studies on glucose-dependent glycosphingolipid biosynthesis , histone acetylation , and MAPK-targeted therapies reveal novel mechanisms in immune and cancer metabolism.

Murray Clarkeمشاهده پروفایل

استاد

• Cardiovascular Diseases
• Cell Death
• Immunology
• +۷ مورد دیگر

Professor Murray Clarke is a PHSA-Engage Mutual Health Professor of Cardiovascular Diseases at the University of Cambridge , affiliated with the Victor Phillip Dahdaleh Heart & Lung Research Institute . He is a leading researcher in cardiovascular immunology, focusing on the interplay between cell death, inflammation, and disease progression. University: University of Cambridge Institute: Victor Phillip Dahdaleh Heart & Lung Research Institute Academic Rank: Professor His research explores mechanisms of inflammation in cardiovascular diseases, particularly the role of interleukin-1 (IL-1) in atherosclerosis, cellular senescence, and immune dysfunction. Key projects include targeting senescent cell-driven vascular inflammation, understanding clonal hematopoiesis in atherogenesis, and dissecting macrophage polarization effects on IL-1 signaling. Recent publications highlight his work on thrombin-activated IL-1α in atherogenesis, non-canonical inflammasome control of the senescence-associated secretory phenotype (SASP), and T cell-intrinsic complement-IL-1R2 axis regulation of immune responses. These studies span immunology, cardiovascular biology, and aging research , emphasizing novel therapeutic targets for inflammatory diseases. Professor Clarke employs cell culture, animal models, and advanced immunoassays to investigate inflammasome activation, IL-1 signaling aberrations, and senescence in disease contexts. His group has identified molecular pathways linking cell death to adaptive immunity, with implications for multiple chronic conditions.

• Vascular Physiology
• Pulmonary Hypertension
• Prostacyclin Signalling
• +۵ مورد دیگر

Professor Lucie Clapp is Professor of Vascular Physiology at University College London (UCL), Institute of Cardiovascular Science, and currently serves as Head of Pre-clinical & Fundamental Science and Deputy Director of the Institute. She has been a faculty member since 1996, progressing from Senior Lecturer to Reader (2002) and full Professor (2005). From 2015 to 2021 she was an elected professorial member of UCL Council. Education: PhD, University of London (1985) BSc (Pharmacology, 2:1), University of Bristol (1981) Post-doctoral fellowship & Instructor in Physiology, University of Massachusetts Medical School, USA (1985-1988) Research Interests: Professor Clapp’s work converges on vascular physiology, pulmonary hypertension, prostacyclin signalling and ion-channel pharmacology . Her laboratory deciphers the biophysical properties of vascular potassium channels and their roles in septic shock, vascular remodelling and pulmonary arterial hypertension (PAH). She explores prostacyclin analogues at membrane and nuclear receptors, with emphasis on PPARγ-mediated pathways and novel receptor targets. Complementary studies focus on circulating biomarkers, mitochondrial dynamics and calcineurin regulation of K ATP channels in smooth muscle. Publication Trends: Across 178 outputs, recent work (2020-2025) centres on prostacyclin mimetics, GPCR pharmacology, microRNA regulation, epigenetic therapeutics and liquid-biopsy biomarkers for cancer and cardiovascular disease, reflecting a seamless integration of fundamental pharmacology with translational medicine. Scientific Awards & Fellowships: Howard Sprague Fellowship, American Heart Association (AHA) Career Development Award, Wellcome Trust Senior Fellowship, Medical Research Council (1996-2006) Fellow, American Heart Association (2001) Fellow, Pulmonary Vascular Research Institute (2010) Fellow, Royal Society of Biology (2011) AstraZeneca Prize for Women in Pharmacology, British Pharmacological Society (2017) Advancement of Learning and Teaching Award, UCL (2013) Teaching, Advising & Grants: Professor Clapp is a passionate educator and mentor. She founded and directs the iBSc in Cardiovascular Science for 3rd-year medical students, leads the Heart & Circulation module (PHOL0007) and lectures on multiple BSc, MSc and PhD programmes. Since 2009 she has co-organised and mentored on the British Heart Foundation 4-year PhD scheme. She has secured long-term funding from the MRC, Wellcome Trust, United Therapeutics and other biotech partners, and has served on editorial boards ( British Journal of Pharmacology , 2009-2015) and grant-review panels worldwide. Labs & Consortia: She heads a vibrant laboratory within the Centre for Cardiovascular Physiology & Pharmacology , Rayne Building, and spearheads the UCL-wide Pulmonary Arterial Hypertension Consortium , uniting clinicians and scientists across affiliated hospitals. This network feeds into the national BRIDGE cohort study and the international Pulmonary Vascular Research Institute (PVRI) , where she sits on the Preclinical & Molecular Science Task Force.

• Vitamin D Biology
• Hormonal Homeostasis
• Phosphodiesterase Inhibitors
• +۴ مورد دیگر

Clara Crescioli is an Associate Professor at the University of Rome 'Foro Italico' within the Department of Human Motor Sciences and Health. Her research focuses on hormonal regulation, vitamin D biology, and the therapeutic potential of phosphodiesterase inhibitors in autoimmune and cardiovascular diseases. She explores the intersection of exercise physiology, endocrinology, and environmental health, with a particular emphasis on sex-specific health outcomes. Her teaching responsibilities include courses on research methodology, motor activity assessment, and specialized topics for developmental and geriatric populations. Dr. Crescioli’s work bridges basic science and clinical applications, often using in vitro models to study drug mechanisms in conditions like systemic sclerosis and diabetic cardiomyopathy. Key research themes include the anti-inflammatory effects of PDE5 inhibitors, vitamin D’s role in aging and immunity, and the impact of environmental toxins on musculoskeletal and cardiovascular health. Her studies frequently involve collaborations across disciplines, integrating molecular biology with clinical observations.

R J. Whiteمشاهده پروفایل

استاد

• Pulmonary Arterial Hypertension (PAH)
• Clinical Research in Rare Lung Diseases
• Preclinical Animal Models of PAH
• +۷ مورد دیگر

R. James White, MD, PhD is a Professor at the University of Rochester Medical Center , holding appointments in the Department of Medicine (Pulmonary Diseases and Critical Care) , Department of Pediatrics (Cardiology) , and Department of Pharmacology and Physiology . As director of the University of Rochester PHA Comprehensive Care Center , he specializes in pulmonary arterial hypertension (PAH) and related conditions like obstructive sleep apnea and heart failure . Education: MD from University of Pittsburgh, PhD through NIH Medical Scientist Training Program Training: Internal Medicine residency and Pulmonary/Critical Care fellowship at University of Rochester Dr. White leads both clinical research and a bench laboratory focused on advancing PAH treatment. His lab develops preclinical models with proliferative vascular lesions and investigates tissue factor inhibition as novel therapy. He chairs global trials for oral treprostinil and contributes to clinical guidelines through steering committees. Recent work emphasizes digital health applications like actigraphy for activity monitoring and telemedicine rehabilitation post-pulmonary embolism. His research spans biomarker discovery (angiopoietin-2, D-dimer), comorbidity management , and multinational treatment patterns . Scientific Recognition: Parker B. Francis Fellowship Buswell Fellowship NIH Training Grant Alpha Omega Alpha Honor Society NIH Medical Scientist Training Program Phi Beta Kappa Dr. White serves as lead researcher in several NIH-funded studies including the PAH Biobank and rituximab trials for scleroderma PAH. His team includes Deb Haight (LVT) , Allison Light (Postdoc) , and clinical staff across multiple departments.

Peter Wrightمشاهده پروفایل

مدرس ارشد

• Cardiovascular Physiology
• Cardiac Cell Biology
• Heart Failure Research
• +۳ مورد دیگر

Peter Wright serves as a Senior Lecturer at the School of Life and Health Sciences, University of Surrey, where he is affiliated with the Centre for Integrated Research in Life and Health Sciences. He maintains an active research profile with 43 total publications, currently accepting PhD students and producing significant output through 2023. His external position as Honorary Research Fellow at Imperial College London (July 2020 - May 2024) demonstrates his collaborative reach across UK institutions. Dr. Wright's research focuses on cardiovascular pathophysiology with particular emphasis on cardiac cell biology in disease states. His work investigates molecular mechanisms in heart failure, pulmonary hypertension, and stress-induced cardiomyopathies like Takotsubo syndrome. Key research themes include microtubule-mediated receptor regulation, cardiomyocyte remodeling in right ventricular dysfunction, and temperature-triggered cardiac events. His methodological expertise spans striated muscle physiology techniques and cellular signaling analysis. Analysis of his recent publications (2022-2023) reveals a strong concentration on translational cardiovascular research, particularly examining β-adrenergic receptor dynamics in failing hearts and the cellular mechanisms underlying pulmonary hypertension. His work bridges basic molecular biology with clinical cardiac conditions, frequently employing advanced cellular imaging and electrophysiological techniques. The publications show consistent collaboration with leading cardiac research groups across multiple UK institutions. As an active PhD supervisor, Dr. Wright contributes to graduate education while maintaining robust research productivity. His publication record shows sustained output since 2011 with 24 articles in the last decade, including high-impact journals like Circulation Research and Cells . His research network spans international collaborations, particularly evident in his work on right ventricular cardiomyocyte remodeling. Dr. Wright's laboratory work centers on cardiac cell physiology, with particular focus on the molecular mechanisms of heart failure and stress-induced cardiac conditions. His research group employs advanced techniques including cellular imaging, electrophysiology, and molecular analysis of cardiomyocyte function, contributing to understanding of temperature-triggered cardiac events and receptor-mediated cardiac dysfunction.

Paul Armstrongمشاهده پروفایل

مدرس

• Pharmacology
• Hematology
• Thrombosis
• +۳ مورد دیگر

Dr. Paul Armstrong is a Lecturer in Pharmacology at the Centre for Immunobiology within the Blizard Institute at Queen Mary University of London. His research focuses on platelet pharmacology, particularly investigating how platelet turnover in disease states influences thrombotic risk and how platelet-monocyte aggregates contribute to disease pathophysiology. These studies aim to refine therapeutic approaches for cardiovascular diseases. Education : BSc in Pharmacology (University of Edinburgh), PhD at William Harvey Research Institute (2009) Research Themes : Platelet Reactivity, Thrombosis, Immune Cell Interaction, Cardiovascular Pharmacology Collaborations : Timothy D Warner's Lab; international institutions like Baker Institute (Australia) His recent publications emphasize platelet aging dynamics, noncoding RNA biomarkers, and novel assay development for platelet function testing. Collaborative studies explore cross-disciplinary approaches in thrombosis and hemostasis. No formal student advising or specific grants mentioned in available texts. Armstrong's work frequently addresses antiplatelet therapy optimization and platelet-endothelium interactions.

• Platelet Biology
• Hemostasis
• Thrombosis
• +۳ مورد دیگر

Dr Simon Calaminus is a Senior Lecturer at the University of Hull, affiliated with the Faculty of Health Sciences and Hull York Medical School. He holds roles as Programme Director for the MSc in Pharmacology and Drug Development and teaches Phase 1 MBBS and Biomedical Science Pharmacology. Education: BSc in Biochemistry and PhD in Platelet Biology from the University of Birmingham (2004–2007), supervised by Prof Steve Watson. Postdoctoral research at the Beatson Institute (2007–2012) under Prof Laura Machesky, focusing on platelet biology and cancer cell signaling. Research Interests Investigates platelet responses to agonists/inhibitors and external pollutants like microplastics. Techniques include platelet spreading, in vitro thrombus formation, FACS analysis, and Western blotting. Recent work explores hypoxia effects on platelet function and quantum dot biocompatibility. Grants & Projects British Heart Foundation: £110k (2023–2025) studying hypoxia's role in prostacyclin-mediated platelet inhibition. Rosetrees Trust: £9k (2024) addressing microplastics as healthcare threats. Co-investigator on MRC/Wolfson imaging equipment grants (2024–2029). Lab & Collaborations Part of the Centre for Biomedicine, focusing on thrombosis, platelet signaling, and nanotechnology applications. Collaborates with industry and NHS experts for translational research.

• Pharmacology
• Biomedical Engineering
• Neuroscience
• +۵ مورد دیگر

Dr. Jeanette C. Perron is an Assistant Professor of Pharmaceutical Sciences at the College of Pharmacy and Health Sciences, St. John’s University. She specializes in drug development, biomaterials, and cellular signaling pathways, with a focus on neuropharmacology, immunology, and regenerative medicine. Dr. Perron teaches courses such as BIOCHEMICAL NEUROPHARMACOLOGY, CLINICAL IMMUNOLOGY, and INTRODUCTION TO PHARMACOLOGY. Her research explores innovative drug delivery systems, including nanoemulgel formulations for brain-targeted therapies, as well as therapeutic interventions for neurodegenerative diseases, inflammatory conditions, and cancer. Recent work includes studies on exosome-based therapies for Alzheimer’s disease, benzimidazole compounds for osteogenic differentiation, and GAT107’s role in mitigating ventilator-associated pneumonia. Her publications highlight advancements in understanding BMP (bone morphogenetic protein) signaling mechanisms in spinal neurons, ethanol toxicity mitigation, and quantum dot-conjugated cancer therapies. Dr. Perron’s interdisciplinary approach bridges pharmacology, bioengineering, and molecular biology, contributing to both academic research and clinical applications. She is affiliated with the College’s pharmaceutical and biomedical research initiatives but no specific lab is explicitly listed in the provided information.

Kevin Cunninghamمشاهده پروفایل

پژوهشگر ارشد

• Ion Channels
• Cardiovascular Disease
• Atrial Fibrillation
• +۴ مورد دیگر

Kevin Cunningham is a Research Fellow at the University of Westminster, serving as the Early and Mid-Career Research Committee Representative. He holds a PhD in Pharmacology and Physiology from the Medway School of Pharmacy (University of Kent), with postdoctoral research at King’s College London and the University of Miami. His work focuses on ion channel dysfunction in diseases like cardiovascular disorders and epilepsy, with expertise in electrophysiology, computational modeling, and drug discovery. Education: BSc (Honours) Pharmacology, Kingston University MSc Cancer Biology, University of Kent PhD in Pharmacology and Physiology, University of Kent (Thesis: Functional Properties and Pharmacological Regulation of Two-Pore Domain Potassium Channels) Research Interests: Channelopathies and ion channel drug targeting Cardiovascular diseases, atrial fibrillation, and pulmonary hypertension Electrophysiological techniques (patch clamp, voltage clamp fluorometry) Computational modeling of ion channel behavior Recent Research Trends: His publications (2020–2025) center on ion channel modulation, particularly HCN channels in neurological disorders and IKs channels in cardiac physiology. Recent work explores propofol’s rescue of epilepsy-linked HCN1 mutations and PUFA effects on IKs selectivity filters, reflecting a shift toward translational research in drug development. Engagement & Awards: Co-ordinator for Pint of Science public engagement Organized Postdoc Appreciation Week at Westminster Supervising doctoral student Laima Tokhi on Kv1.5 targeting for atrial fibrillation Labs & Collaborations: Affiliated with the University of Westminster’s Pathobiology and Extracellular Vesicle Research Group and the Centre for Resilience. Collaborates internationally on HCN, K2P, and KCNQ channel research.

Elizabeth Ashley Hardinمشاهده پروفایل

استادیار

• Cardiology
• Heart Failure
• Pulmonary Hypertension
• +۵ مورد دیگر

Elizabeth Ashley Hardin is an Assistant Professor at UT Southwestern Medical Center, specializing in Cardiology and Heart Failure within the Department of Internal Medicine. She practices at University Hospital Heart and Lung Clinic, William P. Clements Jr. University Hospital, and Parkland Hospital. Education: Dual undergraduate degrees in Biology and Genetics from Texas A&M University, MD from UT Southwestern, residency in Internal Medicine at University of California-San Francisco, and fellowships in Cardiovascular Disease and Advanced Heart Failure at UT Southwestern. Her research focuses on cardiovascular disease, heart failure, and pulmonary hypertension. Key areas include echocardiographic assessment, immunosuppression in transplants, and hemodynamic monitoring. Recent publications emphasize the clinical application of prostacyclin therapy, right heart catheterization, and diuretic strategies in heart failure. Dr. Hardin is affiliated with the American College of Cardiology, International Society for Heart and Lung Transplantation, and Heart Failure Society of America, where she serves on the Annual Scientific Program Committee.

Katie Wraithمشاهده پروفایل

مدرس

• Cardiovascular Biology
• Platelet Function
• Coagulation Pathway
• +۳ مورد دیگر

Katie Wraith is a Lecturer in Cardiovascular Biology at the Hull York Medical School (University of Hull). She leads a laboratory investigating platelet and coagulation pathway dysregulation in cardiovascular diseases, with a focus on oxidized low-density lipoproteins (oxLDL). Education: PhD in Medical Sciences (2013, Hull York Medical School) Career: Post-Doctoral Research Assistant (2013-2017, Naseem Lab); Senior Laboratory Research Scientist (2022-2024, Palmer Lab); Lecturer since 2024 Research Interests: Her work explores how oxLDL amplifies platelet activation and pro-coagulant responses in diseases like atherosclerosis. Key areas include thrombosis mechanisms, lipid metabolism, and signal transduction pathways. Recent Article Trends: Analysis of her publications (2013-2025) reveals consistent focus on oxLDL interactions with platelet receptors (CD36, αIIbβ3), hypoxia effects on platelet function, and dyslipidemia-induced hyperactivity mechanisms. Subfields include antiplatelet therapies, thrombin signaling, and fibrinogen modulation. Teaching: Delivers the Haemostasis and Thrombosis in Cardiovascular Diseases module for MB BS Medicine. Leads independent research projects across Biomedical Science and Health & Climate Change programs. Projects: Principal investigator for the MRC-funded RISE project (2024-2029) establishing super-resolution imaging for multimorbidity research.

Jing Wangمشاهده پروفایل

استادیار

• Empirical Corporate Finance
• Corporate Debt Financing
• Financial Economics
• +۳ مورد دیگر

Jing Wang is an Assistant Professor in the Finance Department at the Robert J. Trulaske, Sr. College of Business, University of Missouri, and holds the Thomas H. Weaver Faculty Scholar title. Her research focuses on empirical corporate finance, particularly corporate debt financing strategies and capital structure decisions. She has published in top journals such as the Journal of Financial Economics and Management Science. Dr. Wang earned her PhD in Finance from Purdue University. Prior to Missouri, she taught corporate finance at Purdue University, Ohio State University, and the University of Nebraska-Lincoln. Her academic roles emphasize both research and pedagogy. Her research interests include analyzing corporate debt markets, capital allocation policies, and financial distress risks. She has explored topics such as firm leverage decisions, debt covenant design, and the interplay between governance structures and financing choices. Recent publications demonstrate her expertise in identifying empirical patterns in corporate finance, with a focus on debt issuance strategies and their macroeconomic implications. Her work bridges theoretical frameworks with real-world financial data to inform managerial and policy decisions. Dr. Wang’s teaching portfolio includes advanced corporate finance courses, reflecting her commitment to educating future finance professionals. She maintains an active research agenda with collaborative projects in corporate governance and fintech applications in debt markets.

Brendan Whittleمشاهده پروفایل

استاد

• Pharmacology
• Gastroenterology
• Pulmonary Vascular Disease
• +۴ مورد دیگر

Professor Brendan Whittle holds the position of Professor of Applied Pharmacology at Queen Mary University of London's William Harvey Research Institute within the School of Medicine. He also serves as a Visiting Professor at the University of Hertfordshire and a visiting lecturer at the University of Tampere, Finland. His academic credentials include a B.Pharm., Ph.D., and D.Sc., complemented by fellowships from the British Pharmacological Society and Royal Society of Medicine. He has been honored with the Gaddum Lecture Prize and the Sandoz Prize. Research interests span pharmacology, gastroenterology, and pulmonary vascular disease, focusing on mechanisms of drug-induced gastrointestinal injury, prostacyclin analogues, and anti-inflammatory therapies for colitis. His industry experience includes 20 years at the Wellcome Research Laboratories, where he led pharmacology teams, and roles at Daiichi Pharmaceuticals and as a consultant for major pharma companies. Key collaborations include work with Professors Lucy Clapp (UCL), Csaba Varga (University of Szeged), and Lenard Lichtenberger (University of Texas). As a Director of William Harvey Research Ltd., he oversees sponsored research. With over 350 peer-reviewed publications and recognition as an ISI Highly Cited Researcher (1980–2000), his contributions to drug development and pre-clinical research are globally acknowledged.